EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.
Issue link: https://digital.eyeworld.org/i/274531
Plan to attend this special session S en. Rand Paul, MD (R- KY), has been announced as the ASCRS•ASOA G overnment Relations Session speaker for the 2014 ASCRS•ASOA Symposium & Congress in Boston. The session is scheduled for Friday, April 25, from 5 to 6 p.m. and will be open to all conference attendees. Following the session, a fundraiser for Sen. Paul will be held. B rock Bakewell, MD, Fishkind, Bakewell and Maltzman Eye Care, Tucson, Ariz., and chair of the ASCRS Government Relations Com- mittee, said the session is one that's not to be missed. "Sen. Paul is a dy- namic speaker who knows first hand the issues faced by physicians," he said. "He is certain to deliver an enthusiastic talk that will resonate positively with most physicians." Before he began serving in the United States Senate, Sen. Paul prac- ticed ophthalmology in Bowling Green, Ky. He has also been a major advocate for the physician's perspec- tive on healthcare policy. Sen. Paul is a co-sponsor of A SCRS•ASOA priority legislation to repeal the Independent Payment Advisory Board (IPAB). He serves on the Senate Health, Education, Labor and Pensions Committee. He is well known as an independent voice on many issues and is an original co- sponsor of legislation to provide a viable Medicare private contracting o ption and to delay the implemen- tation of ICD-10. Prior to serving in the Senate, Sen. Paul owned his own ophthal- mology practice and performed sur- gery for 18 years. He is the founder of the Southern Kentucky Lions Eye Clinic, an organization that provides eye exams and surgery to needy families and individuals. During the Government Relations Session, Sen. Paul will share his perspective on healthcare policy as a physician serving in Congress. EW February 2014 by Ellen Stodola EyeWorld Staff Writer Sen. Rand Paul to be ASCRS•ASOA Government Relations speaker 12:40 PM CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a phy- sician. INDICATIONS: The AcrySof ® IQ Toric posterior chamber intraocular lenses are intended for primary implantation in the capsular bag of the eye for visual correction of aphakia and pre-existing corneal astigmatism second- ary to removal of a cataractous lens in adult patients with or without presbyopia, who de- sire improved uncorrected distance vision, reduction of residual refractive cylinder and increased spectacle independence for dis- tance vision. WARNING/PRECAUTION: Careful preopera- tive evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Toric IOLs should not be implanted if the posterior capsule is ruptured, if the zonules are dam- aged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic cor- rection; if necessary lens repositioning should occur as early as possible prior to lens encap- sulation. All viscoelastics should be removed from both the anterior and posterior sides of the lens; residual viscoelastics may allow the lens to rotate. Optical theory suggests that high astigmatic patients (i.e. > 2.5 D) may experience spatial distortions. Possible toric IOL related factors may include residual cylindrical error or axis misalignments. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon for this product inform- ing them of possible risks and benefits as- sociated with the AcrySof ® IQ Toric Cylinder Power IOLs. Studies have shown that color vision discrim- ination is not adversely affected in individu- als with the AcrySof ® Natural IOL and normal color vision. The effect on vision of the Ac- rySof ® Natural IOL in subjects with hereditary color vision defects and acquired color vision defects secondary to ocular disease (e.g., glaucoma, diabetic retinopathy, chronic uve- itis, and other retinal or optic nerve diseases) has not been studied. Do not resterilize; do not store over 45° C; use only sterile irrigating solutions such as BSS ® or BSS PLUS ® Sterile Intraocular Irrigating Solutions. ATTENTION: Reference the Directions for Use labeling for a complete listing of indications, warnings and precautions. © 2013 Novartis 2/13 TOR13020JAD www.AcrySofIQTORIC.com S en. Rand Paul, MD SPECIAL ASCRS•ASOA GOVERNMENT RELATIONS SESSION U.S. SENATOR RAND PAUL, MD (R-KY) FRIDAY, APRIL 25 5:00–6:00 PM BOSTON CONVENTION & EXHIBITION CENTER SYMPOSIUM & CONGRESS 2014 APRIL 25–29 B O S T O N